Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: Relevance to parkinson disease

Antioxidants and Redox Signaling

Volumn 17, Issue 11, 2012, Pages 1490-1506

  Di Domenico, Fabio ^a,b   Sultana, Rukhsana ^a   Ferree, Andrew ^c   Smith, Katelyn ^c   Barone, Eugenio ^a,d   Perluigi, Marzia ^b   Coccia, Raffaella ^b   Pierce, William ^e   Cai, Jian ^e   Mancuso, Cesare ^d   Squillace, Rachel ^f   Wiengele, Manfred ^f   Dalle Donne, Isabella ^g   Wolozin, Benjamin ^c,h   Butterfield, D Allan ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c BOSTON UNIVERSITY   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f ARIAD PHARMACEUTICALS INC   (United States)

^g UNIVERSITY OF MILAN   (Italy)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; MITOCHONDRIAL PROTEIN; RIBOSOME PROTEIN; TAU PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; AUTOPHAGY; CAENORHABDITIS ELEGANS; DEGENERATIVE DISEASE; GENE; GENE EXPRESSION; LIPID PEROXIDATION; LRRK2 GENE; MUTATIONAL ANALYSIS; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEOMICS; WESTERN BLOTTING;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; AUTOPHAGY; CAENORHABDITIS ELEGANS; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; LIPID PEROXIDATION; MITOCHONDRIAL PROTEINS; MUTATION; NERVE DEGENERATION; OXIDATION-REDUCTION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; PROTEOME; TAU PROTEINS;

CAENORHABDITIS ELEGANS;

EID: 84866663422     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4312     Document Type: Article

References (61)

1. Abou-Sleiman PM, Muqit MM, and Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219, 2006. (Pubitemid 43292466)
2. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, and Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18: 4022-4034, 2009.
3. Alegre-Abarrategui J and Wade-Martins R. Parkinson disease, LRRK2 and the endocytic-autophagic pathway. Autophagy 5: 1208-1210, 2009.
4. Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, and Butterfield DA. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: Insights into memory loss in MCI. J Alzheimers Dis 23: 257-269, 2011.
5. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J,Mouatt-Prigent A, RubergM,Hirsch EC, and Agid Y.Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12: 25-31, 1997. (Pubitemid 27106916)
6. Boyd-Kimball D, Poon HF, Lynn BC, Cai J, Pierce WM, Jr., Klein JB, Ferguson J, Link CD, and Butterfield DA. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): Implications for Alzheimer's disease. Neurobiol Aging 27: 1239-1249, 2006. (Pubitemid 44067304)
7. Butterfield DA, Bader Lange ML, and Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 1801: 924-929, 2010.
8. Chan D, Citro A, Cordy JM, Shen GC, and Wolozin B. Rac1 Protein rescues neurite retraction caused by G2019S leucinerich repeat kinase 2 (LRRK2). J Biol Chem 286: 16140-16149, 2011.
9. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279: 13256-13264, 2004. (Pubitemid 38445905)
10. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, and Li L. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280: 11648-11655, 2005. (Pubitemid 40418479)
11. Dachsel JC and Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol 67: 542-547, 2010.
12. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, and Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64: 816-830, 2005. (Pubitemid 41285815)
13. Dalle-Donne I, Scaloni A, and Butterfield DA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases New York: John Wiley and Sons; 2006.
14. Devine MJ and Lewis PA. Emerging pathways in genetic Parkinson's disease: Tangles, Lewy bodies and LRRK2. FEBS J 275: 5748-5757, 2008.
15. Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, Goldwurm S, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER, Italian Parkinson Genetics N, and Bonifati V. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68: 1557-1562, 2007. (Pubitemid 46717978)
16. Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet 7: 306-318, 2006.
17. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272, 1996. (Pubitemid 26085575)
18. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC, and Parkinson Study G. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60: 796-801, 2003. (Pubitemid 36297363)
19. Galpern WR and Lang AE. Interface between tauopathies and synucleinopathies: A tale of two proteins. Ann Neurol 59: 449-458, 2006. (Pubitemid 43358065)
20. Gloeckner CJ, Schumacher A, Boldt K, and Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109: 959-968, 2009.
21. Gomez A and Ferrer I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 87: 1002-1013, 2009.
22. Gomez A and Ferrer I. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol 120: 155-167, 2010.
23. Guthrie CR, Schellenberg GD, and Kraemer BC. SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Hum Mol Genet 18: 1825-1838, 2009.
24. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, and Hattori N. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16: 678-690, 2007. (Pubitemid 46585667)
25. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, and Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27: 2432-2443, 2008.
26. Kraemer BC, Burgess JK, Chen JH, Thomas JH, and Schellenberg GD. Molecular pathways that influence human tauinduced pathology in Caenorhabditis elegans. Hum Mol Genet 15: 1483-1496, 2006.
27. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, and Schellenberg GD. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA 100: 9980-9985, 2003. (Pubitemid 37087054)
28. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, and Cookson MR. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357: 668-671, 2007. (Pubitemid 46653831)
29. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, and Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103: 238-247, 2007. (Pubitemid 47404210)
30. Li Y, Dunn L, Greggio E, Krumm B, Jackson GS, Cookson MR, Lewis PA, and Deng J. The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim Biophys Acta 1792: 1194-1197, 2009.
31. Lin CH, Tsai PI, Wu RM, and Chien CT. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J Neurosci 30: 13138-13149, 2010.
32. LinMT and BealMF.Mitochondrial dysfunction and oxidative stress in neurodegenerativediseases.Nature 443: 787-795, 2006. (Pubitemid 44622683)
33. Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, Hoglinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC, Vanier MT, Vonsattel JP, Wagner S, and Wszolek ZK, Reisensburg Working Group for Tauopathies With P. Tauopathies with parkinsonism: Clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 16: 297-309, 2009.
34. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, and Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-593, 2006. (Pubitemid 44781171)
35. Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Kruger R, Hattori N, Mellick GD, Quattrone A, Satoh J, Toda T, Wang J, Ioannidis JP, de Andrade M, and Rocca WA, Consortium UGG. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 55: 512-521, 2004. (Pubitemid 38391968)
36. Martinez-Vicente M and Cuervo AM. Autophagy and neurodegeneration: When the cleaning crew goes on strike. Lancet Neurol 6: 352-361, 2007. (Pubitemid 46367949)
37. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, and Gallo KA. LRRK2 in Parkinson's disease: Protein domains and functional insights. Trends Neurosci 29: 286-293, 2006.
38. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gaukhman A, Yu X, Castanedes-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, and Farrer MJ. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40: 503-517, 2010.
39. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC, Jr., and Lau YS. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 956: 156-165, 2002. (Pubitemid 35335568)
40. Nuytemans K, Rademakers R, Theuns J, Pals P, Engelborghs S, Pickut B, de Pooter T, Peeters K, Mattheijssens M, Van den Broeck M, Cras P, De Deyn PP, and van Broeckhoven C. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet 16: 471-479, 2008. (Pubitemid 351420380)
41. Pan T, Kondo S, Le W, and Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131: 1969-1978, 2008.
42. Plowey ED, Cherra SJ, 3rd, Liu YJ, and Chu CT. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.JNeurochem105: 1048-1056, 2008. (Pubitemid 351565713)
43. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, Cobb SA, Rajput ML, and Farrer MJ. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67: 1506-1508, 2006. (Pubitemid 44632090)
44. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, and Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38: 1184-1191, 2006. (Pubitemid 44470365)
45. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, and Clackson T. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 10: 1059-1071, 2011.
46. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443: 780-786, 2006. (Pubitemid 44622682)
47. Saha S,GuillilyMD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, SegalL,RaghavanK,MatsumotoK,HisamotoN,Kuwahara T, Iwatsubo T, Moore L,Goldstein L, CooksonM, and Wolozin B. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29: 9210-9218, 2009.
48. Santpere G and Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathol 117: 227-46, 2009.
49. Schapira AH. Mitochondrial dysfunction in neurodegenerative diseases. Neurochem Res 33: 2502-2509, 2008.
50. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, Hatano T, Hattori N, Kim KS, Chang S, and Seol W. LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314: 2055-2065, 2008.
51. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, and Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231-1233, 2006. (Pubitemid 44454261)
52. Squillace RM, Miller D, Cookson M, Wardwell SD, Moran L, Clapham D, Wang F, Clackson T, and Rivera VM. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 10: 1959-1968, 2011.
53. Sultana R and Butterfield DA. Identification of the oxidative stress proteome in the brain. Free RadicBiolMed 50: 487-494, 2011.
54. Taylor JP, Mata IF, and Farrer MJ. LRRK2: A common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med 12: 76-82, 2006. (Pubitemid 43202125)
55. Taymans JM and Cookson MR. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 32: 227-235, 2010.
56. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C, Liu L, Przedborski S, and Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280: 42655-42668, 2005. (Pubitemid 43049224)
57. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, and Dawson TM. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102: 16842-16847, 2005. (Pubitemid 41688864)
58. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, and Dawson TM. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232, 2007. (Pubitemid 46179004)
59. Wszolek ZK, Tsuboi Y, Ghetti B, Pickering-Brown S, Baba Y, and Cheshire WP. Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Orphanet J Rare Dis 1: 30, 2006.
60. Yang Q and Mao Z. Parkinson disease: A role for autophagy? Neuroscientist 16: 335-341, 2010.
61. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607, 2004. (Pubitemid 39531225)